Terumo (TRUMY) Stock Price, News & Analysis

Company Overview

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags. Through its Terumo BCT subsidiary, the company also provides apheresis, blood component management and cell therapy technologies used by blood banks, transfusion services and cell-therapy developers. Terumo’s portfolio emphasizes single-use medical devices and clinically oriented systems designed to improve procedural outcomes and patient safety.

Founded in the early 20th century and headquartered in Tokyo, Terumo has grown into a multinational supplier with operations and sales networks across Asia, the Americas and Europe. The company distributes products globally through a combination of regional subsidiaries, direct sales teams and distribution partners, serving hospitals, specialty clinics and blood centers. As a publicly listed Japanese corporation, Terumo also maintains an American depositary receipt (ADR) listing that enables trading on overseas markets.

Key Stats

• Today's Range: $14.17 to $14.23
• 50-Day Range: $12.15 to $15.14
• 52-Week Range: $12.08 to $19.60
• Volume: 198,963 shs
• Average Volume: 255,581 shs
• Market Capitalization: $20.92 billion
• P/E Ratio: 23.25
• Dividend Yield: 0.49%
• Price Target: N/A
• Consensus Rating: Hold

Terumo Stock Analysis - MarketRank™

Terumo scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Terumo has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Terumo has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 9.52%

Earnings Growth

Earnings for Terumo are expected to grow by 9.52% in the coming year, from $0.63 to $0.69 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Terumo is 23.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.11.

Price to Earnings Ratio vs. Sector

The P/E ratio of Terumo is 23.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 18.89.

Price to Book Value per Share Ratio

Terumo has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Terumo has been sold short.

Short Interest Ratio / Days to Cover

Terumo has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Terumo has recently decreased by 54.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Terumo has a dividend yield of 0.46%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Terumo does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Terumo is 11.48%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Terumo will have a dividend payout ratio of 10.14% next year. This indicates that Terumo will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Terumo has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Terumo insiders have not sold or bought any company stock.

Percentage Held by Institutions

Terumo has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:TRUMY
• Previous Symbol: NASDAQ:TRUMY
• CIK: 1446672
• Web: www.terumo.co.jp
• Phone: (133) 374-8111
• Fax: 813-3374-8399
• Employees: 30,000
• Year Founded: 1964

Profitability

• EPS (Trailing Twelve Months): $0.61
• Trailing P/E Ratio: 23.25
• Forward P/E Ratio: 22.51
• P/E Growth: N/A
• Net Income: $902.88 million
• Net Margins: 12.09%
• Pretax Margin: N/A
• Return on Equity: 9.35%
• Return on Assets: 6.81%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 1.51
• Quick Ratio: 0.89

Sales & Book Value

• Annual Sales: $7.52 billion
• Price / Sales: 2.78
• Cash Flow: $0.90 per share
• Price / Cash Flow: 15.67
• Book Value: $6.10 per share
• Price / Book: 2.32

Miscellaneous

• Outstanding Shares: 1,475,070,000
• Free Float: N/A
• Market Cap: $20.92 billion
• Optionable: Not Optionable
• Beta: 0.67